机构投资者调整AbbVie的股份,尽管收入亏损和股息支付率高。 Institutional investors adjust holdings in AbbVie despite earnings miss and high dividend payout ratio.

沙丘全球顾问和其他机构投资者调整了在AbbVie公司持有的股份,该公司是一家制药公司,市场上限为3 300亿美元。 Sand Hill Global Advisors and other institutional investors have adjusted their holdings in AbbVie Inc., a pharmaceutical company with a market cap of $330 billion. 尽管AbbVie报告收入亏损,但AbbVie有一个一致的“机动买”评级,目标价格为211.45美元。 Despite reporting an earnings miss, AbbVie has a consensus "Moderate Buy" rating and a target price of $211.45. 该公司提供像Humira和Skyrizi这样的产品,其强劲的红利收益率为3.52%。 The company offers products like Humira and Skyrizi and has a strong dividend yield of 3.52%. 然而,259.41%的高支付比率令人对其红利的可持续性感到关切。 However, the high payout ratio of 259.41% raises concerns about the sustainability of its dividend.